Hypophosphatasia is an hereditary disease characterized by low activity of total serum alkaline phosphatase (TALP) accompanied by a range of skeletal diseases. We have measured the main circulating alkaline phosphatase isoenzymes ± bone (BALP), liver (LALP), intestinal (IALP), placental (PALP) ± in six families with hypophosphatasia, using kinetic and electrophorectic methods. Our observations show that patients with skeletal disease tend to have a very low BALP activity. Patients even with undetectable LALP activity do not appear to manifest any clinical complications. Patients also showed proportionately high IALP activity. Since the production of signi®cant IALP activity is not a constant feature in all healthy individuals, it remains to be established whether the survival of one of these patients (IALP 80% of TALP) depended on the presence of circulating IALP.
INTRODUCTION
Hypophosphatasia is a rare inherited disorder characterized by low levels of serum alkaline phosphatase (EC 3.1.3.1) and a range of skeletal diseases. Hypophosphatasia has been classi®ed into different clinical types: perinatal, infantile, childhood, adult, odontohypophosphatasia and pseudohypophosphatasia. In its severest form death may occur in utero from severe skeletal malformation (perinatal hypophosphatasia), whereas in its mildest adult form there may be very minor or no skeletal disease. A number of phosphorylated metabolites ± urinary phosphoethanolamine and pyrophosphate and serum pyridoxal phosphate ± are raised. 1 Although the perinatal and infantile types of hypophosphatasia are inherited as an autosomal recessive trait, the adult type may be inherited as an autosomal dominant trait. 2, 3 Hypophosphatasia is now known to result from mutations in the tissue non-speci®c alkaline phosphatase (TNSALP) gene. 4 Tissue non-speci®c alkaline phosphatase includes enzymes produced in many tissues with varying physicochemical properties, including liver alkaline phosphatase (LALP) and bone alkaline phosphatase (BALP). In healthy, nonpregnant subjects, these are the main circulating types of alkaline phosphatases. Alkaline phosphatases released from the placenta (PALP), intestine (IALP) and germ cell, which are products of separate genes, are also released into the circulation. 5 Measurement of total serum alkaline phosphatase (TALP) activity has, clinically, long been used as a diagnostic test. In order to increase the diagnostic speci®city and sensitivity, a plethora of methods have been developed to measure selectively the alkaline phosphatase isoenzymes, especially to differentiate between LALP and BALP. 6, 7 The exact incidence of hypophosphatasia in different parts of the world is not known. Fraser has reported an incidence of 1 100 000 in Toronto, Canada. 8 As far as we know, clinical hypophosphatasia is a rare condition and, although cases of hypophosphatasia have been reported worldwide, there are few published reports on the value of measuring alkaline phosphatase isoenzymes in hypophosphatasia and their relationship to the clinical features of this disorder. Measurements of alkaline phosphatase isoenzymes have only been made in single cases 9±11 or in single families. 10, 12 One study from Germany has looked at isoenzymes in ten unrelated cases of hypophosphatasia. 13 It has been suggested that the main circulating form of alkaline phosphatase in hypophosphatasia is derived from the intestine. 9 Others have reported no such increase, but a relative decrease in proportion of bone or liver isoenzymes. 12 Very few studies have been able to study the full complement of the main circulating isoenzymes of alkaline phosphatase in hypophosphatasia in a number of families. We therefore examined alkaline phosphatase isoenzymes in six different families to see how these would relate to the clinical features. Table 1 )
MATERIALS AND METHODS

Patients (see
The index patient of this family (1:2,c*) was diagnosed as having adult-onset hypophosphatasia, with short stature (height 147 cm, 3rd centile) and loss of teeth by the age of 20 years. She presented at the age of 47 years, with bowing of her legs and a waddling gait. She had two daughters delivered by caesarean section, having had one stillbirth because of a deformed pelvis. She had characteristic biochemical features of hypophosphatasia. Her results were: TALP 13 IU/L, pyridoxal phosphate 783 nmol/L (reference range 97), urinary phosphoethanolamine 50 mmol/mmol creatinine (Cr) ( 10) . This patient has been previously reported to have a persistently raised serum acid phosphatase activity. 14 Her two daughers (1:3,f and 1:3,g) also had biochemical features of hypophosphatasia without clinical bone disease.
Family 2
The index case was a lady (2:2,a*) who presented at the age of 24 years with bone pain and pyrophosphate arthropathy. Her results were: TALP 26 IU/L, serum pyridoxal phosphate 289 nmol/L, urinary phosphoethanolamine 21 mmol/mmol Cr, pyrophosphate 16 mmol/ mmol Cr. Her father (2:1,b) and brother (2:2,b) were also affected, but did not have symptomatic bone disease.
Family 3
The index case was a male patient (3:2,a*) who had childhood rickets, but a diagnosis of hypophosphatasia had not been made until the age of 41 years. He showed kyphoscoliosis and short height, and reported bone pain. His results were: TALP 32 IU/L, pyridoxal phosphate 2409 nmol/L, urine phosphoethanolamine 47 mmol/mmol Cr, pyrophosphate 29 mmol/ mmol Cr.
Family 4
Following the detection of gross skeletal abnormalities of a fetus during a pregnancy and subsequent termination, the two parents were identi®ed as being heterozygotes for hypophosphatasia. The father's (4:1,a) results were: TALP 49 IU/L, pyridoxal phosphate 166 nmol/L, urinary phosphoethanolamine 21 mmol/mmol Cr, pyrophosphate 6´0 mmol/ mmol Cr. The mother (4:2,b) had: TALP 41 IU/L, pyridoxal phosphate 200 nmol/L (on vitamin B 6 supplements), urinary phosphoethanolamine 12 m mol/mmol Cr, pyrophosphate 21 mmol/mmol Cr.
Family 5
The index case (5:2,a*) of this family was aged 32 years at the time of presentation and was found to have hypophosphatasia on a routine blood pro®le where her TALP was noted to be low. Further family screening con®rmed the presence of low alkaline phosphatase in her two siblings and a borderline low alkaline phosphatase in her father. Her mother was found to have a normal alkaline phosphatase activity. No member of this family was reported to have any skeletal problems, history of stillbirth or early loss of dentition. Further full details are available on the sister (5:2,c).
Family 6
The index case (6:2,a) was a male aged 45 years with retinitis pigmentosa who presented with back pain. Routine biochemistry showed him to have a low TALP (15 IU/L), pyridoxal phosphate 268 mmol/L, urinary phosphoethanolamine 75 mmol/mmol Cr. His sister was already known to suffer from hypophosphatasia, but further details were not available.
Mode of inheritance
The mode of inheritance in families 1, 2, 5, and possibly 6, is likely to be autosomal dominant, whereas in families 3 and 4 it is autosomal recessive.
Methods
Alkaline phosphatase activity with and without L-homoarginine and phenylalanine inhibition
Total serum alkaline phosphatase was measured using a Sigma ALP kit, which contained diethanolamine buffer, pH 9´8, 1´214 mol/L, magnesium 0´607 mmol/L, p-nitrophenyl phosphate 60´8 mmol/L (Sigma Diagnostics, St Louis, USA). Aliquots of the buffer substrate solutions were made up as directed. In addition, further aliquots of buffer substrates were made up containing L-homoarginine, an inhibitor of TNSALP-type alkaline phosphatase, at a ®nal concentration of 20´0 mmol/L in buffer substrate, 15 and L-phenylalanine, an inhibitor of IALP and PALP, at a ®nal concentration of 5 mmol/L in buffer substrate. 16 Reactions were carried out in a Cobas Bio centrifugal analyser (Roche Diagnostics, Lewes, UK) at 37 C and readings were taken at 405 nm. L-Homoarginine inhibits LALP and BALP to approximately 80% of true total value, and inhibits IALP to approximately10%. 16 L-Phenylalanine inhibits IALP to approximately 80% of true total value and inhibits BALP and LALP to approximately 10%. 16 In order to obtain true BALP and LALP and IALP the normogram given in reference 16 was used.
Placental alkaline phosphatase
The characteristic property of PALP is its heat stability at 65 C. Aliquots of all test serum samples were heated to 65 C for 30 min; the remaining alkaline phosphatase activity was determined and any residual activity was taken as PALP. 17 
Electrophoresis
The liver and bone alkaline phosphatase isoenzymes were determined using the Hydrogel Iso-pal electrophoresis gels system (Sebia Moulineaux, France). This system has two agarose gels; one of the gels, the`af®nity gel', contains lectin. After sample (5 mL) application, electrophoresis was carried out using barbital buffer containing sodium azide. The gels were stained with a substrate solution containing indolyl phosphate±nitroblue tetrazolium salt; the alkaline phosphatase bands stain a purple colour. The lectin in the`af®nity gel' retards the migration of the bone band cathodally while the liver band migrates anodally. The bands were well resolved in this system. Once dried, the gels were scanned on a Hyrys densitometer (Sebia Ltd, Moulineaux, France) which allows calculation of the percentage and position of each of the enzyme bands. Knowing the total alkaline phosphatase activity and the percentage of the liver and bone bands from the electrophoresis, bone and liver alkaline phosphatase activities were calculated.
The algorithm for determining alkaline phosphatase isoenzymes was: ALP activity remaining after heating serum at 65 C for 30 min was taken as PALP ( 1 IU/L for all samples). True ALP was determined from L-phenylalanine inhibition after correction using a normogram. 16 True BALP+LALP was determined from L-homoarginine inhibition after correction using a nomogram. 16 Percentage of LALP and BALP was determined by electrophoresis and densitometric scanning.
Using percentage LALP and percentage BALP derived from electrophoresis, LALP and BALP were calculated from the true Lhomoarginine-inhibited fraction.
Within-run precision (CV) (n=7) at low TALP (45 IU/L) was 4% and 5% for BALP and LALP (21 IU/L), respectively. At normal levels of TALP (94 IU/L), CV was 5% for BALP (21 IU/L) and 3% for LALP (73 IU/L). Between-run precision (n=6) at TALP of 17 IU/L was: BALP (7 IU/L) 16%, LALP (10 IU/L) 11%; between-run precision at TALP of 51 IU/L was: BALP (13 IU/L) 20%, LALP (38 IU/L) 7%. Reference values for BALP, LALP and IALP determined in 16 healthy subjects (age range 28±67 years, ten men, six women) were: TALP 124±132 IU/L, LALP 72± 80 IU/L, BALP 41±49 IU/L, IALP 0±4 IU/L. Pyridoxal 5 0 -phosphate was measured using high-performance liquid chromatography (HPLC). Urinary phosphoethanolamine was measured with an amino acid analyser using ion-exchange gradient HPLC on a Biochrom 20 analyser (Pharmacia Biotech Ltd, Cambridge, UK). Table 1 shows the ALP isoenzymes in the patients and families.
RESULTS
In all serum samples, the TALP activity after heating the sample at 65 C was 1 IU/L, indicating insigni®cant PALP activity. IALP activity in most patients was low. Because of the poorer sensitivity of the electrophoretic methods, IALP bands were only observed in three patients (3:2,a, 5:2,a and 6:2,a). In these patients, IALP was a signi®cant proportion of the TALP, especially in subject 3:2,a. Electrophoresis showed low but varying proportions of BALP and LALP. LALP was undetectable in patients 1:2,c, 3:2,a, 5:2,a and 6:2,a.
DISCUSSION
Using methods capable of detecting all the major circulating forms of alkaline phosphatase, we have shown that patients with hypophosphatasia exhibit a range of isoenzymes patterns.
Perhaps the most notable feature is that patients with hypophosphatasia who have bone pain and deformity (patients 1:2,c, 2:2,a, 3:2,a and 6:2,a) all have low BALP isoenzyme activity, the patient with the lowest BALP (3:2,a) having the severest skeletal deformity. Some patients, however, with low BALP activity (1:3,f, 1:3,g and 2:1,b) were free of any skeletal deformity or symptoms throughout their life ± one patient (2:1,b) up to the age of 67 years. BALP has a pyrophosphatase activity, and low BALP activity will lead to accumulation of pyrophosphate, an inhibitor of bone mineralization. Insuf®cient mineralization of bone will lead to excess osteoid, deformity and possibly stress fractures and bone pain. Excess osteoid is a feature of this condition 1 and has been shown by bone biopsy in one of our symptomatic patients (1:2,c*). 14 Our ®ndings are consistent with those of Whyte et al., 18 who reported that low immunoreactive BALP activity was re¯ected in the severity of bone disease. Hosen®eld and Hosen®eld, 13 in their study of ten unrelated patients with hypophosphatasia (seven infantile, two childhood and one adult type), reported reduced BALP. Full clinical details of these patients were not given so it is dif®cult to relate low BALP to disease severity. BALP activity characteristically rises during the adolescent growth spurt, sometimes up to three or four times the normal adult limits. 19 As has been pointed out, careful interpretation of alkaline phosphatase activity is required in peripubertal subjects who may be suspected of having hypophosphatasia. 1 Although we have been unable to follow any such patients during the growth spurt, these patients presumably have been able to produce an increased but somewhat submaximal rise in BALP. In contrast, low LALP activity in patients 1:2,c*, 2:2,b, 3:2,a*, 5:2,a* and 6:2,a* was not associated with hepatic dysfunction or other notable clinical features. Reduced LALP activity was also reported in two other studies, apparently also without any clinical effects. 12, 13 Patient (3:2,a*) from family 3, who had severe skeletal disease from childhood, was largely producing IALP isoenzyme with virtually no LALP and minimal, if any, BALP; this was perhaps the underlying reason for the development of his skeletal symptoms. Recently, Whyte et al. 20 studied three female carriers for hypophosphataemia during pregnancy and observed that TALP increased due to an increase in PLAP and that the blood and urine concentrations of phosphorylated substrate decreased.
They suggested that PLAP was responsible for the hydrolysis of these endogenous phosphorylated substrates. Two other patients (5:2,a and 6:2,a) also had signi®cant IALP activity. It must remain speculative whether the high IALP levels functioned in a similar fashion in these subjects. We are not aware of the ABO blood group of these patients as the presence of certain blood groups is associated with the presence of IALP in blood. 20 Our ®ndings of raised IALP in some patients with hypophosphatasia are consistent with previous studies. 8, 13 The proportion of the normal population with IALP detectable by an electrophoretic method has been reported to be 25±30%. 19 Amongst the other members of our families, we know of two members (1:3,f and 2:2,a*) who have undergone pregnancy and produced healthy infants. A rise in the PALP was documented in one of our patients (1:3,f). 22 PALP is well known to rise in pregnancy in patients with hypophosphatasia as this isoenzyme is a product of a different gene. 1 As is recognized and described in our patients, the principal clinical features of hypophosphatasia relate to the defects produced in mineralizing tissue, skeleton and teeth. Our observations support the notion that very low levels of BALP re¯ect the severity of bone involvement, but not invariably so; some subjects with moderately low BALP did not have any skeletal disease and one subject with signi®cant BALP activity had moderately severe skeletal disease. These differences may be due to qualitative differences in BALP activity in vivo. Even undetectable LALP activity did not appear to produce any clinical complication. Only a small proportion of the normal population show detectable IALP activity. In one of our patients, IALP was the major alkaline phosphatase isoenzyme ± whether this was responsible for his survival remains speculative.
